No increase in anti‐A isohemagglutinin titer after SARS‐CoV‐2 infection: A retrospective cohort analysis of group O apheresis platelet donors. Issue 6 (30th September 2021)

• Record Type: Journal Article
• Authors: Wasiluk, Tomasz; Bujno, Magdalena; Rybinska, Kamila; Rogowska, Anna; Zebrowska, Agnieszka; Boczkowska‐Radziwon, Barbara; Piszcz, Jaroslaw; Bolkun, Lukasz; Radziwon, Piotr
• Is Part Of: Journal of clinical apheresis. Volume 36:Issue 6(2021)
• Page Start: 882
• Page End: 885
• Publication Date: 2021-09-30
• Subjects: COVID‐19 -- isohemagglutinin -- platelet -- SARS‐CoV‐2 -- transfusion; Hemapheresis -- Periodicals; Blood -- Transfusion -- Periodicals; Blood -- Transfusion, Autologous -- Periodicals; Cell separation -- Periodicals; Leukapheresis -- Periodicals; Plasmapheresis -- Periodicals; 615.39
• DOI: 10.1002/jca.21942
• Languages: English
• ISSNs: 0733-2459

Abstract

Abstract: The risk of a hemolytic reaction during the transfusion of ABO non‐identical PC is determined by the presence of natural anti‐A IgM antibodies, the titer of which may increase after infections. The aim of the study was to evaluate the titer of anti‐A isohemagglutinins in platelet concentrate (PC) obtained by apheresis from group O donors who experienced SARS‐CoV‐2 infection, and to compare the titer before and after infection. A retrospective single‐center analysis of 21 PC donors with a previous COVID‐19 history was performed. The results showed neither a statistically important increase in the anti‐A IgM antibody titers nor a significant correlation between the anti‐A IgM antibody level and anti‐SARS‐CoV‐2S1 antibody titer in the donors with an asymptomatic or mild COVID‐19. Further population‐based studies on anti‐A titers are necessary for a comprehensive assessment of this phenomenon.